Introduction
============

MicroRNAs (miRNAs or miRs) are small non-coding RNAs, comprising 19--25 nucleotides, that reduce the abundance and translational efficiency of mRNAs and play a major role in regulatory networks, influencing diverse biological processes through the effects of individual miRNAs on the translation of multiple mRNAs ([@b1-ol-0-0-4031],[@b2-ol-0-0-4031]). Determining the roles of individual miRNAs in cellular regulatory processes poses a major challenge with the function of the majority of miRNAs that are currently unknown; even for relatively well-studied miRNAs, only a handful of targets have been rigorously characterized and these may differ by tissue type.

miRNAs post-transcriptionally regulate the expression of thousands of genes, including key genes in cell differentiation and cancer pathogenesis ([@b3-ol-0-0-4031]). A growing number of studies have highlighted the role of miRNAs in the development and progression of cancer ([@b4-ol-0-0-4031],[@b5-ol-0-0-4031]). In particular, the aberrant expression of cancer-related proteins, such as oncogenes and tumor suppressors has been shown to correlate with the modulation of the expression specific miRNAs.

Non-Hodgkin\'s lymphomas (NHLs) are a heterogeneous group of malignancies of the lymphoid system. NHLs are classified based on cytology, immunophenotype and both genetic and clinical characteristics ([@b6-ol-0-0-4031]). Genetic aberration and molecular changes are used for a more appropriate diagnostic profile. The most commonly associated genetic abnormality in NHL is the translocation of t(14;18)(q32;q21) ([@b7-ol-0-0-4031]), mostly detected in low-grade lymphomas, such as follicular lymphoma; while molecular rearrangements involving Bcl-6 or c-Myc are frequently observed in diffuse large B-cell lymphoma (DLBCL) and Burkitt\'s lymphoma (BL), respectively. Currently, a significant percentage of patients with NHL are successfully cured; however, a fraction of these patients may relapse following treatment due to the development of chemoresitance ([@b8-ol-0-0-4031],[@b9-ol-0-0-4031]).

It has been demonstrated that the transcription factor, Yin Yang 1 (YY1), is involved in the regulation of resistance to chemotherapy and immunotherapy in NHL cell lines. In addition, the regulation of Fas resistance by nuclear factor (NF)-κB is mediated via YY1 expression and activity ([@b10-ol-0-0-4031]). YY1 is known to play a critical role in normal biological processes, such as embryogenesis, differentiation, replication and cell proliferation. YY1 exerts its effects on genes involved in these processes through its ability to initiate, activate, or repress transcription, depending upon the context in which it binds ([@b11-ol-0-0-4031]).

It has also been reported that YY1 is overexpressed in several malignancies, including B-cell NHL ([@b12-ol-0-0-4031],[@b13-ol-0-0-4031]), and this overexpression is associated with aggressive behaviour in NHL ([@b14-ol-0-0-4031]). Based on these findings, in the current study, miRNAs potentially capable of targeting and modulating YY1 were identified through *in silico* approaches.

Data collection methods
=======================

In order to identify putative miRNAs that target YY1 mRNA, several publicly available miRNA target prediction tools were used, including DIANA-microT ([@b15-ol-0-0-4031]), miRanda ([@b16-ol-0-0-4031]), PicTar ([@b17-ol-0-0-4031]) and TargetScanS ([@b18-ol-0-0-4031]). Publicly available Gene Expression Omnibus datasets of NHL specimens with the relative normal counterparts were analyzed. Only datasets with both mRNA and miRNA expression levels were considered for the analysis. According to these criteria, the dataset GSE23026 was used in our study ([@b19-ol-0-0-4031]). This dataset includes 12 samples of BL, 5 tonsil specimens, 7 lymph node specimens and 4 samples of CD19^+^CD10^+^ B-cells.

### Statistical analysis

The differential analysis of YY1 expression levels was performed using the ANOVA test. Correlation analysis between the miRNA expression and YY1 expression levels was performed using the Pearson correlation test.

Results
=======

The analysis using the Diana-microT, miRanda, PicTar, TargetScanS tools revealed a total of 57 predicted miRNAs capable of targeting YY1 ([Fig. 1](#f1-ol-0-0-4031){ref-type="fig"}).

The search of publicly available NHL datasets, including paired mRNA and miRNA data (GSE23026) highlighted a significant negative correlation (Pearson correlation coefficient ≤-0.5) between the YY1 expression levels and the expression of a limited set of miRNAs, including miR-363, miR-200a, miR-23b, miR-15a and miR-15b among the 57 predicted miRNAs capable of targeting YY1 ([Table I](#tI-ol-0-0-4031){ref-type="table"}).

As was expected, the transcript expression levels of YY1 were found to be significantly higher in the BL samples compared to the normal tissue samples (mean value expression for BL=0.458, tonsil=−0.248, lymph node=0.049 and CD19^+^CD10^+^ B-cells=0.197; ANOVA, P=0.007) ([Fig. 2](#f2-ol-0-0-4031){ref-type="fig"}). Intriguingly, both hsa-miR-363 and hsa-miR-200a belong to the top 20 miRNAs that were found to be downregulated in the BL samples compared to their normal counterparts ([Table II](#tII-ol-0-0-4031){ref-type="table"}).

Discussion
==========

A growing body of evidence has indicated that deregulated miRNA expression is observed in a variety of human diseases, including lymphomas, suggesting an important role in their pathogenesis ([@b20-ol-0-0-4031],[@b21-ol-0-0-4031]). The data from several experimental studies have supported an important role for miRNAs in lymphomagenesis through systematic miRNA profiling in lymphoma samples using a variety of miRNA expression platforms ([@b22-ol-0-0-4031]--[@b24-ol-0-0-4031]).

YY1 is an activator and a repressor transcription factor belonging to the Zinc-finger proteins ([@b25-ol-0-0-4031]). It is a positive regulator of several oncogenes, such as c-Fos ([@b26-ol-0-0-4031]), c-Myc ([@b27-ol-0-0-4031]) and Erb-B2 receptor tyrosine kinase 2 (ERBB2) ([@b28-ol-0-0-4031],[@b29-ol-0-0-4031]). However, it is also a negative regulator of a fraction of tumor suppressor genes, including p27 ([@b30-ol-0-0-4031]), p16 ([@b31-ol-0-0-4031]), p73 ([@b32-ol-0-0-4031]) and p53 ([@b33-ol-0-0-4031]). YY1 plays a role in the malignant transformation of several diseases, including B-cell lymphomas. Based on these findings, the aim of the present study was to identify, through *in silico* approaches, which miRNAs are potentially capable of targeting and modulating YY1.

Computational evaluation is an appropriate approach for an initial screening to identify deregulated miRNAs. Based on our results, we speculated that YY1 overexpression may be caused by the downregulation of both hsa-miR-363 and hsa-miR-200a, at least in BL. In fact, the overexpression of YY1 negatively correlated with the expression of hsa-miR-363 and hsa-miR-200a. In turn, the expression levels of hsa-miR-363 and hsa-miR-200a were lower in the BL samples when compared with the normal tissue samples. The increased transcript levels of YY1 in the BL samples is in agreement with the observations of a previous study in which the expression of YY1 was found to be associated with high-grade lymphomas, suggesting that it is linked with post-germinal center transit, where genetic alterations may occur, such as Bcl-6 mutations and/or Bcl-6 translocations ([@b34-ol-0-0-4031]). These findings may provide further insight into the pathogenesis of BL, and YY1 may thus be considered as a molecular signature of aggressiveness in high-grade lymphomas.

Notably, it has been previously reported that the overexpression of YY1 may promote p53 degradation or inhibit its transcriptional activity ([@b35-ol-0-0-4031]). Furthermore, the inhibition of YY1 in cancer cells, which lack functional p53, also sensitizes them to cell death in response to apoptotic stimuli ([@b36-ol-0-0-4031],[@b37-ol-0-0-4031]). Although p53 is seldom mutated in NHL, the p53 pathway has been reported to be attenuated in these tumors ([@b38-ol-0-0-4031]). Among the targets of p53, miR-34a has been found to be repressed as a consequence of promoter methylation ([@b39-ol-0-0-4031]). These findings support the notion that YY1 may directly control the expression of genes involved in the apoptotic machinery independently of the p53 protein. However, certain drug-resistant hematopoietic disorders that exhibit wild-type p53 may benefit from targeted therapy ([@b40-ol-0-0-4031]).

In agreement with our results, the loss of miR-200a expression in primary cutaneous melanoma is considered as an additional indicator of aggressiveness, as it was associated with increased thickness and disease progression ([@b41-ol-0-0-4031]).

Low levels of miR-200a have also been observed in mucosa-associated lymphoid tissue lymphoma (MALT) lymphoma of the conjunctiva. It was also found that cyclin E2 is a target of miR-200a ([@b42-ol-0-0-4031]). Accordingly, the putative role of YY1 in tumorigenesis is sustained by its interaction with cell cycle regulation. The downregulated expression of miR-363 can precisely differentiate the high-grade lymphomas into ABC or GCB subtypes, and its expression has been shown to correlate with the clinical outcome ([@b43-ol-0-0-4031]). Similarly, the downregulation of miR-363 has also been detected in ovarian cancer and has been shown to be associated with the drug-resistance phenomenon ([@b44-ol-0-0-4031]).

Although further validation studies are warranted, the results of the present study indicate that the negative correlation between miR-200a and miR-363 and YY1 expression, which is observed in BL, may provide further insight into the pathogenesis of BL and may have implications on treatment strategies. Furthermore, our data suggest that miRNA expression profiling provides a useful tool for a better understanding of cancer development and progression and for the identification of molecular predictors of response and outcome.
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###### 

Pearson correlation analysis between microRNAs targeting YY1 and YY1 expression levels.

  miRNA                                                       Pearson correlation (r≤-0.5)   miRNA ID
  ----------------------------------------------------------- ------------------------------ ----------------
  ^[a](#tfn1-ol-0-0-4031){ref-type="table-fn"}^hsa-miR-363    −0.611                         A_25_P00010953
  ^[a](#tfn1-ol-0-0-4031){ref-type="table-fn"}^hsa-miR-200a   −0.608                         A_25_P00010209
  hsa-miR-23b                                                 −0.577                         A_25_P00010881
  hsa-miR-200a                                                −0.576                         A_25_P00010208
  hsa-miR-15a                                                 −0.552                         A_25_P00010467
  ^[a](#tfn1-ol-0-0-4031){ref-type="table-fn"}^hsa-miR-363    −0.549                         A_25_P00010954
  hsa-miR-15b                                                 −0.517                         A_25_P00011101

MicroRNAs (miRNAs or miRs) belonging to the top 20 miRNAs that were found to be differentially expressed in Burkitt\'s lymphoma samples compared to the normal tissue samples. YY1, Yin Yang 1.

###### 

Top 20 microRNAs downregulated in Burkitt\'s lymphoma samples compared to normal tissue samples.

  miRNA               P-value    FC (log)   miRNA ID
  ------------------- ---------- ---------- ----------------
  hsa-miR-150         2.32E-04   −3.991     A_25_P00010490
  hsa-miR-150         3.13E-04   −3.869     A_25_P00010489
  hsa-miR-363         1.71E-04   −3.745     A_25_P00010954
  hsa-miR-99a         1.10E-06   −3.686     A_25_P00010471
  hsa-miR-10b_v9.1    5.03E-05   −3.657     A_25_P00010136
  hsa-miR-10b_v9.1    3.53E-05   −3.607     A_25_P00010135
  hsa-miR-139_v9.1    2.73E-05   −3.594     A_25_P00010349
  hsa-miR-363         9.85E-05   −3.547     A_25_P00010953
  hsa-let-7g_v9.1     7.09E-06   −3.431     A_25_P00010306
  hsa-miR-31_v9.1     6.93E-05   −3.426     A_25_P00010510
  hsa-let-7g_v9.1     5.21E-06   −3.404     A_25_P00010305
  hsa-miR-200b_v9.1   1.01E-03   −3.389     A_25_P00010908
  hsa-let-7a          7.41E-07   −3.37      A_25_P00011584
  hsa-let-7f          1.59E-06   −3.335     A_25_P00010088
  hsa-miR-195         5.00E-06   −3.25      A_25_P00010769
  hsa-miR-133b        7.41E-04   −3.233     A_25_P00010963
  hsa-miR-195         9.00E-06   −3.198     A_25_P00010770
  hsa-let-7e_v9.1     1.04E-06   −3.192     A_25_P00010280
  hsa-miR-200a        8.78E-04   −3.184     A_25_P00010209
  hsa-let-7e_v9.1     6.81E-07   −3.181     A_25_P00010279

Analysis of microRNAs (miRNAs or miRs) was performed using GEO2R tools. FC, fold change.
